Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
https://www.telegraph.co.uk/news/2022/06/24/polio-what-symptoms-vaccine-schedule-how-catch-treatment/
No treatment, bit like Covid 19... but can leave you paralysed
Why not try something different Tim ;) Sure as hell the big pharma's be scratching their heads and banging em against the walls, would only add to value to keep us all on our toes :)
"living for today"
enjoy your weekend all ;)
https://www.youtube.com/watch?v=X0VTHLa_SgE
https://www.fiercepharma.com/pharma/pfizer-may-have-a-lot-going-immunology-but-all-its-drugs-could-be-beaten-by-rivals-analyst
Big boys are on the hunt, could be sooner than we think ;)
UKRI know exactly what 1801 is all about, imagine numerous indications ... funded 80%
we'd be 10p in a flash, UKRI wouldn't dish out if they didn't think it could do a P2a trial in style ;)
whichever way Sareum go, its win win guys..
Oh if it does decide to plummet back to a quid on delays, in goes my £20k allowance for this year ;)
GLAVLTH's ;)
https://www.ukri.org/opportunity/developmental-pathway-funding-scheme/
could Sareum be applying again?
been a while since I last looked, but has been updated since Sierra joining GSK's party
Moved off the shelf to the front window, site more attractive reading for a suiter..;)
http://www.sareum.com/development/overview/
Agree BB, 10 involved 2 offers, well GSK presence would have put the others of, especially once billions are mentioned ;)
We haven't long to wait, Sareum will soon be history and its molecules on an amazing journey on a cure for many, on so many fronts, mind boggling, Sareum need to let the big pharma's move this on now, at what price WHO knows ;)
GLALTH's its been a very long journey, our time is imminent, keep holding guys, gotta be in it to win it ;)
Did someone say it 3 times!!
After this weekends pathetic appearance, left themselves gob's wide open,
they must think were thick! just hold tight, another nappy has just been soiled, our news flow is so close ..
just hold, and hold tight, our molecules are now in the pharma hot spots of all time,
thank you GSK checkpoint inhibitors, Ner nah ner ner nah ;)
https://www.ukri.org/about-us/strategy-plans-and-data/our-budget/
https://www.ukri.org/wp-content/uploads/2022/05/UKRI-Budget-Allocations-2022-25_FINAL2.pdf
Tyk Tock, now they need to start spending it ;)
https://topic.echemi.com/a/jak-inhibitors-are-accelerating-in-china_226157.html
The JAK-STAT pathway is one of the few immunomodulatory pathways that have been proven so far, so JAK inhibitors can play a role in the field of autoimmune diseases
.
At present, JAK has found four family members: ?JAK1: mainly associated with acute lymphoblastic leukemia, acute myeloid leukemia, solid organ malignancies; ?JAK2: mainly associated with polycythemia vera, myelofibrosis, essential thrombocythemia ?JAK3: mainly related to acute megaloblastic leukemia, T-cell leukemia, lymphoma and other diseases; ?TYK2: mainly related to skin lymphoproliferative diseases and T-cell leukemia
.
However, the potential dangers of JAK1 inhibitors are gradually being exposed
.
Especially in the past two years, the FDA has issued a warning about the increased risk of serious heart-related events, cancer, blood clots and death caused by JAK inhibitors, and has repeatedly delayed the review of JAK inhibitor drugs.
attention to risk
.
How to solve the problem of JAK inhibitor safety and drug resistance in the future will become a problem that pharmaceutical companies strive to solve
Well well well, wont be long before our little Sareum's gems start to kick the pants of the dirty ones out there ;)
Hi Krone, yes, my eyes were also drawn the use of Metformin. T2 Diabetes Used for over 50 years..
1801, may well be the next big thing, the minds boggling, guts telling me were on the brink of something really special, but s/p being suppressed, maybe work of potential big pharma heavies trying to T/O for a pittance of our real worth...
Time will tell
https://www.dovepress.com/current-strategies-in-treating-cytokine-release-syndrome-triggered-by--peer-reviewed-fulltext-article-ITT
interesting to date reading, and we all wait patiently ;)
These companies are all part of the "drug manufacturers - major" industry
Nice to see our Sareum included as a major!! ;)
https://www.marketbeat.com/stocks/LON/GSK/competitors-and-alternatives/
It doesn't get much clear than this:
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer. In addition to momelotinib, the pipeline consists of two assets in phase I SRA515 and SRA737. SRA515 is a selective bromodomain-containing protein 4 (BRD4) bromodomain and extra-terminal domain (BET) inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, and SRA737 is a novel checkpoint kinase 1 (CHK1) inhibitor.
GSK all the way, to me, sareum are probably negotiating lock stock and barrels buy out ;)
https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/
Yep, In addition to momelotinib, the pipeline consists of two assets in phase I SRA515 and SRA737.
Have a great Easter break All ;)
https://www.science.org/doi/pdf/10.1126/sciadv.abj3887
For the science heavyweights ;)
I couldn't get past the introduction..